Biomarkers of intermediate endpoints in environmental and occupational health

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Biomarkers of intermediate endpoints in environmental and occupational health. / Knudsen, Lisbeth E; Hansen, Ase M.

In: International Journal of Hygiene and Environmental Health, Vol. 210, No. 3-4, 2007, p. 461-70.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Knudsen, LE & Hansen, AM 2007, 'Biomarkers of intermediate endpoints in environmental and occupational health', International Journal of Hygiene and Environmental Health, vol. 210, no. 3-4, pp. 461-70. https://doi.org/10.1016/j.ijheh.2007.01.015

APA

Knudsen, L. E., & Hansen, A. M. (2007). Biomarkers of intermediate endpoints in environmental and occupational health. International Journal of Hygiene and Environmental Health, 210(3-4), 461-70. https://doi.org/10.1016/j.ijheh.2007.01.015

Vancouver

Knudsen LE, Hansen AM. Biomarkers of intermediate endpoints in environmental and occupational health. International Journal of Hygiene and Environmental Health. 2007;210(3-4):461-70. https://doi.org/10.1016/j.ijheh.2007.01.015

Author

Knudsen, Lisbeth E ; Hansen, Ase M. / Biomarkers of intermediate endpoints in environmental and occupational health. In: International Journal of Hygiene and Environmental Health. 2007 ; Vol. 210, No. 3-4. pp. 461-70.

Bibtex

@article{dae4bb800b4011df825d000ea68e967b,
title = "Biomarkers of intermediate endpoints in environmental and occupational health",
abstract = "The use of biomarkers in environmental and occupational health is increasing due to increasing demands on information about health risks from unfavourable exposures. Biomarkers provide information about individual loads. Biomarkers of intermediate endpoints benefit in comparison with biomarkers of exposure from the fact that they are closer to the adverse outcome in the pathway from exposure to health effects and may provide powerful information for intervention. Some biomarkers are specific, e.g., DNA and protein adducts, while others are unspecific like the cytogenetic biomarkers of chromosomal aberrations (CA), sister chromatid exchanges and micronuclei (MN). The validation of biomarkers includes measurements of sensitivity and specificity of biomarkers and round robin tests to ensure reproducible protocols within different laboratories. The predictive value of biomarkers with respect to adverse health effect from the result of the measurement has been performed for the cytogenetic biomarkers showing a predictive value of high levels of CA and increased risk of cancer. The use of CA in future studies is, however, limited by the laborious and sensitive procedure of the test and lack of trained cytogeneticists. Less time consuming, but robust biomarkers, sensitive to environmental exposures are suggested. From the selection of developed biomarkers, the comet assay is highly sensitive to lifestyle exposures, often confounding the output, while MN in lymphocytes seem promising with respect to laboratory and health effect (cancer) validity. Also, new biomarkers exploiting the new 'omics' technologies are being developed. A number of ethical issues arise from the use of biomarkers with a predictive value aiming at respecting the autonomy of the study person in participation (only upon written informed consent and with obligations of withdrawal at any time), access to personal information (right to know and right not to know the study result) and securing proper data management (data protection to avoid misuse in employment, insurance, loaning and learning opportunities).",
author = "Knudsen, {Lisbeth E} and Hansen, {Ase M}",
note = "Keywords: Accidents, Occupational; Acetylcholinesterase; Acrylamide; Animals; Biological Markers; Chromosome Aberrations; DNA Adducts; Environmental Monitoring; Evaluation Studies as Topic; Hemoglobins; Humans; Hydrocortisone; Micronuclei, Chromosome-Defective; Mutagenicity Tests; Occupational Exposure; Pesticides; Predictive Value of Tests; Proteins; Rats; Reproducibility of Results; Stress, Psychological",
year = "2007",
doi = "10.1016/j.ijheh.2007.01.015",
language = "English",
volume = "210",
pages = "461--70",
journal = "International Journal of Hygiene and Environmental Health",
issn = "1438-4639",
publisher = "Elsevier GmbH - Urban und Fischer",
number = "3-4",

}

RIS

TY - JOUR

T1 - Biomarkers of intermediate endpoints in environmental and occupational health

AU - Knudsen, Lisbeth E

AU - Hansen, Ase M

N1 - Keywords: Accidents, Occupational; Acetylcholinesterase; Acrylamide; Animals; Biological Markers; Chromosome Aberrations; DNA Adducts; Environmental Monitoring; Evaluation Studies as Topic; Hemoglobins; Humans; Hydrocortisone; Micronuclei, Chromosome-Defective; Mutagenicity Tests; Occupational Exposure; Pesticides; Predictive Value of Tests; Proteins; Rats; Reproducibility of Results; Stress, Psychological

PY - 2007

Y1 - 2007

N2 - The use of biomarkers in environmental and occupational health is increasing due to increasing demands on information about health risks from unfavourable exposures. Biomarkers provide information about individual loads. Biomarkers of intermediate endpoints benefit in comparison with biomarkers of exposure from the fact that they are closer to the adverse outcome in the pathway from exposure to health effects and may provide powerful information for intervention. Some biomarkers are specific, e.g., DNA and protein adducts, while others are unspecific like the cytogenetic biomarkers of chromosomal aberrations (CA), sister chromatid exchanges and micronuclei (MN). The validation of biomarkers includes measurements of sensitivity and specificity of biomarkers and round robin tests to ensure reproducible protocols within different laboratories. The predictive value of biomarkers with respect to adverse health effect from the result of the measurement has been performed for the cytogenetic biomarkers showing a predictive value of high levels of CA and increased risk of cancer. The use of CA in future studies is, however, limited by the laborious and sensitive procedure of the test and lack of trained cytogeneticists. Less time consuming, but robust biomarkers, sensitive to environmental exposures are suggested. From the selection of developed biomarkers, the comet assay is highly sensitive to lifestyle exposures, often confounding the output, while MN in lymphocytes seem promising with respect to laboratory and health effect (cancer) validity. Also, new biomarkers exploiting the new 'omics' technologies are being developed. A number of ethical issues arise from the use of biomarkers with a predictive value aiming at respecting the autonomy of the study person in participation (only upon written informed consent and with obligations of withdrawal at any time), access to personal information (right to know and right not to know the study result) and securing proper data management (data protection to avoid misuse in employment, insurance, loaning and learning opportunities).

AB - The use of biomarkers in environmental and occupational health is increasing due to increasing demands on information about health risks from unfavourable exposures. Biomarkers provide information about individual loads. Biomarkers of intermediate endpoints benefit in comparison with biomarkers of exposure from the fact that they are closer to the adverse outcome in the pathway from exposure to health effects and may provide powerful information for intervention. Some biomarkers are specific, e.g., DNA and protein adducts, while others are unspecific like the cytogenetic biomarkers of chromosomal aberrations (CA), sister chromatid exchanges and micronuclei (MN). The validation of biomarkers includes measurements of sensitivity and specificity of biomarkers and round robin tests to ensure reproducible protocols within different laboratories. The predictive value of biomarkers with respect to adverse health effect from the result of the measurement has been performed for the cytogenetic biomarkers showing a predictive value of high levels of CA and increased risk of cancer. The use of CA in future studies is, however, limited by the laborious and sensitive procedure of the test and lack of trained cytogeneticists. Less time consuming, but robust biomarkers, sensitive to environmental exposures are suggested. From the selection of developed biomarkers, the comet assay is highly sensitive to lifestyle exposures, often confounding the output, while MN in lymphocytes seem promising with respect to laboratory and health effect (cancer) validity. Also, new biomarkers exploiting the new 'omics' technologies are being developed. A number of ethical issues arise from the use of biomarkers with a predictive value aiming at respecting the autonomy of the study person in participation (only upon written informed consent and with obligations of withdrawal at any time), access to personal information (right to know and right not to know the study result) and securing proper data management (data protection to avoid misuse in employment, insurance, loaning and learning opportunities).

U2 - 10.1016/j.ijheh.2007.01.015

DO - 10.1016/j.ijheh.2007.01.015

M3 - Journal article

C2 - 17321211

VL - 210

SP - 461

EP - 470

JO - International Journal of Hygiene and Environmental Health

JF - International Journal of Hygiene and Environmental Health

SN - 1438-4639

IS - 3-4

ER -

ID: 17264703